BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Computer Sciences Corporation (CSC) Wins $35.1 Million National Institute of Allergy, Infectious Disease Contract For Development Of Tularemia Vaccine


10/19/2005 5:13:18 PM

EL SEGUNDO, Calif., Oct. 5 /PRNewswire/ -- Computer Sciences Corporation today announced that DVC LLC, a CSC company, has been awarded a five-year, $35.1 million contract from the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health, to develop candidates for a safe and effective tularemia vaccine.

Under the terms of the contract, DVC will develop and optimize preclinical testing models, assess immune response and develop new tularemia vaccine candidates.

Teaming with DVC are Umea University, Sweden; the Defence Science and Technology Laboratory (a component of the UK Ministry of Defence), United Kingdom; and the National Research Council of Canada (NRC Institute for Biological Sciences).

Tularemia is a zoonotic disease caused by the bacterium Francisella tularensis, which has been identified as a potential biological threat agent. Tularemia is extremely infectious, with disease resulting from exposure to as few as 10 organisms. Inhalation of tularemia leads to a form of pneumonia that can cause significant rates of mortality if untreated.

"These properties make tularemia one of the top potential candidates for an agent of biowarfare or bioterrorism," said DVC Chief Scientific Officer Dr. Robert V. House. "Our team is well-positioned to make great advances in developing a safe and effective vaccine against this dangerous organism."

NIAID is a part of the National Institutes of Health, an agency of the U.S. Department of Health and Human Services. NIAID conducts and supports research that strives to understand, treat and ultimately prevent the myriad of infectious, immunologic and allergic diseases that threaten hundreds of millions of people worldwide.

DVC is a biodefense company dedicated to the development and licensure of safe and effective biological products. DVC is part of CSC's Enforcement, Security and Intelligence organization, which CSC created in 2001 to support programs enhancing U.S. security.

This project has been funded 100 percent with federal funds from the NIAID, the National Institutes of Health, and the Department of Health and Human Services under contract no. N01-AI-50041.

About Canada's National Research Council

Recognized globally for its research and innovation, Canada's National Research Council (NRC) is a leader in the development of an innovative, knowledge-based economy for Canada through science and technology. NRC operates world-class research facilities as well as information, technology and innovation support networks for partners in Canada and internationally. For more information, please visit the NRC Web site at www.nrc-cnrc.gc.ca.

With over 75 years of research excellence, the NRC Institute for Biological Sciences (NRC-IBS) consists of a team of leading life science researchers dedicated to spearheading the next breakthrough discoveries and technologies in neurobiology, immunobiology and glycobiology. Driven by these challenges, NRC-IBS is focused on innovative research of interest to the healthcare and pharmaceutical sectors in the areas of neurodegenerative and infectious diseases.

About CSC

Founded in 1959, Computer Sciences Corporation is a leading global information technology (IT) services company. CSC's mission is to provide customers in industry and government with solutions crafted to meet their specific challenges and enable them to profit from the advanced use of technology.

With approximately 78,000 employees, CSC provides innovative solutions for customers around the world by applying leading technologies and CSC's own advanced capabilities. These include systems design and integration; IT and business process outsourcing; applications software development; Web and application hosting; and management consulting. Headquartered in El Segundo, Calif., CSC reported revenue of $14.3 billion from continuing operations for the 12 months ended July 1, 2005. For more information, visit the company's Web site at www.csc.com.

Computer Sciences Corporation

CONTACT: April Finnen, Manager, Public Relations of DVC LLC,+1-301-607-5004, afinnen@csc.com; or Rich Venn, Media Relations, Corporate,+1-310-615-3926, rvenn@csc.com, or Bill Lackey, Director, InvestorRelations, Corporate, +1-310-615-1700, blackey3@csc.com, both of ComputerSciences Corporation



Read at BioSpace.com

   
Vaccine

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES